Фиксированная комбинация амлодипина и валсартана: кому же она необходима в первую очередь?

1. Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563–80.
2. Poldermans D, Glazer R, Karagianniss S et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29: 279–89.
3. Trenkwalder P, Schaetzl R, Borbas E et al. Efficacy and safety of the combination of amlodipine 10/valsartan 160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5 – the EXPRESS-C trial. J Hypertens 2007; 25 (Suppl. 2): S228 (abstract P24.261).
4. Allemann Y, Fraile B, Lambert M et al. Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens (Greenwich) 2008; 10(3): 185–94.
5. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. JAMA 2003; 289: 2560–72.
6. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
7. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиоваск. тер. и профил. 2004; Прил.
8. Smith TR, Phillipp T, Vaisse B et al. Amlodipine and valsartan combination and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analysis of 2 randomized, placebo-controlled studies. J Clin Hypertens 2007; 9: 355–64.
9. Sposito AC. Emerging insights into hypertension and dyslipidaemia sinergies. Eur Heart J 2004; 6 (suppl. G): G8–G12.
10. Wang Ji-G, Staessen JA, Li Y et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006; 37: 1933–40.
11. Dahlof B et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumetiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
12. Mancini GB, Miller ME, Evans GW et al. Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT). Am J Cardiol 2002; 89: 1414–6.
13. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102: 1503–10.
14. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–25.
15. Peters S, Gotting B, Trummel M et al. Valsartan for Prevention of Restenosis After Stenting of Type B2/C Lesions: The Val- PREST trial. J Invas Cardiol 2001; 13: 93–7.
16. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.
17. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Сердечн. недостат. 2007; 8 (2).
18. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20: 1461–4.
19. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–8.
20. Hollenberg NK, Parving HH, Viberti G. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921–6.
21. Destro M, Luckow A, Samson M et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens 2008; 24: 5–8.

Ю.М.Лопатин

Волгоградский государственный медицинский университет,
Волгоградский областной кардиологический центр